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INTRODUCTION
Clinical staging and therapy planning of laryngeal tumors is based on the TNM classifi cation 
concerning tumor size and extension and metastatic spread to cervical lymph nodes or 
other organs. It has been shown that tumor stage is the only independent prognostic 
variable in head and neck tumors, despite an intensive search for other pathological and 
biological predictive factors 1. However, tumors with similar clinical stage may respond 
to therapy diff erently 2, indicating that morphological parameters used in the TNM 
classifi cation are not suffi  cient for an accurate estimation of individual treatment outcome 
and prognosis. 
The behavior of disease is suggested to be related to the metabolic activity of 
tumors. In vitro, the metabolic activity is assessed by histological parameters as mitotic 
activity, proliferation and diff erentiation. Although high mitotic rate, high proliferation and 
loss of diff erentiation represent aggressive tumor growth in general, these parameters have 
not been included in the routine staging or therapy planning of laryngeal carcinomas. 
In the past years it has been shown that tumor metabolism can be determined 
in vivo by positron emission tomography (PET), in which radiopharmaceuticals labeled 
with positron-emitting nuclides are used to assess metabolic and pathophysiological 
processes. The glucose analogue 2-[18F]-fl uoro-2-deoxy-D-glucose (FDG) is the most widely 
used radiopharmaceutical in PET and the application of FDG-PET has been successful for a 
variety of malignancies 3, including primary head and neck cancers and metastatic cervical 
lymph nodes 4,5. Relations between in vivo glucose consumption as measured by FDG-PET 
and in vitro tumor grade have been described for diff erent tumor types 6. In head and neck 
tumors, the relations between metabolic FDG uptake and histopathologic parameters 
were controversial in several studies 7-9. Furthermore, FDG is not tumor specifi c, due to 
accumulation in benign lesions and infl ammatory tissues 10.
Amino acids are less avidly metabolized by infl ammatory cells and therefore 11C-
labeled amino acids were introduced as radiotracers 11. Uptake of amino acids in tumor 
tissue is high, due to an increased protein synthesis 12. Methyl-labeled 11C-methionine 
(MET) is the most frequently used amino acid, mainly due to the relative ease of synthesis. 
However, the position of the 11C-label does not allow for quantitative studies 11. L-[1-11C]-
tyrosine (TYR), a carboxyl-labeled amino acid, is an appropriate compound to determine 
protein synthesis activity in tumor tissue and by using a dynamic scanning procedure, 
quantifi cation of the Protein Synthesis Rate (PSR) of tumor tissue is possible 13. TYR-PET has 
been successfully used in detection and quantifi cation of diff erent primary and recurrent 
tumors, including head and neck malignancies 14-18.
The aim of the current study was to investigate the presence of relations between 
in vivo tumor metabolism using TYR-PET and in vitro biological activity of laryngeal 







TYR-PET was performed in twenty-fi ve patients, 22 men and 3 women, with a histologic 
diagnosis of squamous cell carcinoma of the larynx (Table 1). Tumors were clinically 
staged by physical examination of head and neck, endoscopic examination under 
general anesthesia, biopsies of all suspicious areas of the upper aerodigestive tract and 
CT imaging according to the TNM classifi cation system (UICC, 1997) 19. Median age at the 
time of diagnosis was 64 years (range 46-80 yr). The locations of the twenty-fi ve tumors 
were 40% glottic, 56% supraglottic  and 4% transglottic. The diameter of all tumors was 
larger than 15 mm.
Table 1
Patient and tumor characteristics
  Characteristics     Number  
   Men      22
  Women        3
  Primary site
   Larynx    
    glottic    10
    supraglottic   14
    transglottic     1
  Primary tumor 
   T1       1
   T2     12
   T3       6
   T4       6
  Lymph nodes
   N0     19
   N1       1
   N2       5
   N3       0
  Histological grade
   G1       9
   G2     10 
   G3       6
  UICC stage
   I       1
   II       9
   III       5
   IV     10 
UICC = International Union Against Cancer (1997)
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The TYR-PET study was approved by the medical ethics committee of the Groningen 
University Hospital and written informed consent was obtained from all subjects. 
Curative therapy was planned according to the type, location and stage of the 
disease. Thirteen patients received defi nitive megavoltage radiotherapy with a conventional 
fractionation schedule to a total absorbed tumor dose of 66-70 Gy, 2 Gy per fraction, fi ve 
fractions weekly. Surgery was performed in 12 patients by total laryngectomy, including 
neck dissection in six subjects. All operated patients received additional radiotherapy to 
the tumor dose of 60-70 Gy  in 30-35 fractions.
Histological examination
In all patients, histological diagnosis was made on haematoxilin-eosin stained paraffi  n 
sections, with or without additional immuno histological stains, of tumor tissue obtained 
by diagnostic biopsy during endoscopy. The squamous cell carcinomas were graded 
according to the UICC grading system 19 (Table 1). Of the twelve patients who underwent 
total laryngectomy, histological comparison between the larynx specimen and the 
biopsies was performed to determine possible sampling errors. 
 The percentage of mitotic fi gures was counted in ten fi elds on haematoxilin-
eosin stained paraffi  n sections. Proliferating cells were detected using the monoclonal 
antibody MIB-1 (DAKO, Glostrup, Denmark), which recognises an epitope of the Ki-67 
antigen. Ki-67 is a nuclear antigen present in all parts of the cell cycle except for the G-
zero phase of the cell cycle (G0), in which cells are withdrawn from the cell cycle, and 
the early Gap 1 phase (G1), the phase of the cell cycle before the start of DNA synthesis. 
Immunohistochemistry was performed on paraffi  n sections (4 μm) according to a method 
modifi ed from Shi et al. 20. Briefl y, after heating on a hot plate, slides were dewaxed in 
xylene and rehydrated in serial ethanol washes (100%, 96% and 70%). After one night 
heating at 80 oC in 0.1 M Tris/HCl buff er solution pH=9.0, peroxidase was blocked using 
0.3% H2O2. Subsequently, the slides were incubated with the MIB-1 antibody in 1% BSA/
PBS (pH=7.4) for 1 hour at room temperature in a humidifi ed chamber. The primary 
antibody was detected with a rabbit antimouse (DAKO, Glostrup, Denmark) peroxidase 
labeled secondary antibody diluted in 1:50 + 1% human serum (type AB) followed by 
incubation with goat antirabbit conjugated peroxidase diluted in 1:50 +1% human serum 
(type AB). 3.3-diaminobenzidine tetrahydrochloride (Sigma, St. Louis, USA) with imidazole 
(Merck KgaA, Darmstadt, Germany) in PBS was used as the chromagen according to the 
manufacturer’s instructions. After counterstaining with Mayer’s haematoxylin, the slides 
were dehydrated through graded alcohols and mounted with coverslips.
For determining the percentage of mitotic cells and the Ki-67 labelling index 
(LI), we used ocular micrometry on a microscope by using an eyepiece grid at x400 
magnifi cation. Ten fi elds were randomly selected throughout histologically viable tumor 
areas. Endothelial cells, infl ammatory cells and necrosis were excluded. The number of 
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mitotic fi gures and the Ki-67 positive nuclei was then divided by the total number of 
nuclei in each of the ten fi elds to calculate the percentage of dividing and proliferating 
cells per fi eld. The percentage of mitotic cells and the Ki-67 LI was defi ned as the mean of 
the indices of the ten fi elds.
PET
Dynamic TYR-PET studies were performed in all twenty-fi ve patients. TYR was produced 
via a modifi ed microwave induced Bücherer-Strecker synthesis 21. Synthesis time was 40 
minutes, including high performance liquid chromatography (HPLC) purifi cation and 
testing for sterility, with a radiochemical purity over 99%. 
The PET images were acquired using an ECAT 951/31 PET camera (Siemens/CTI, 
Knoxville, TN). This device has a 56-cm-diameter patient aperture and acquires 31 planes 
simultaneously. The axial fi eld-of-view is 10.8-cm and the resolution is 6 mm full width of 
half maximum (FWHM). The head of the patient was fi xed in a position with the Frankfurter 
horizontal plane (line between the external meatus acusticus and the lower orbital rim) 
making an angle of 110° with the horizontal bed position. Patients fasted for at least 8 hr 
(except for water and their usual medication) before the study. 
A venous canula was placed in the antecubital vein of the forearm for injection of 
TYR. In the radial artery of the contralateral arm an arterial canula was placed under local 
anaesthesia. Before injection of TYR, a 20 min transmission scan using a 68Ge/68Ga-source 
was obtained to correct for photon attenuation by body tissues in the imaged area. TYR 
was administered intravenously over a 1 min period. The median injected dose was 368 
MBq (range 144-399 MBq). Dynamic scanning with 16 time frames was performed from 
the time of injection to 50 minutes post-injection at the level of the tumor. The protocol 
included ten 30-seconds images, three 5-minutes images and three 10-minutes images. 
Simultaneously, arterial blood samples were taken at set time points in order to assess 
TYR plasma time-activity curve, 11CO2 concentration and other 
11C-labeled metabolites 
by radio-HPLC 13. The plasma tyrosine levels were assessed and ranged from 0.031-0.087 
mmol/L, which is within normal values for our laboratory and in accordance with values 
reported in the literature.
PET data analysis
PET data were reconstructed using fi ltered backprojection by a 0.5 cycle/pixel Hann-fi lter 
to obtain transaxial images which were displayed applying standard ECAT software.
 To determine tumor PSR, a region of interest (ROI) was placed in the plane with 
most intense uptake at the site of the tumor as observed at visual analysis, using a 70% 
threshold of maximum intensity. The tissue time-activity curve obtained from this ROI, 
together with the plasma-input data (MBq/ml TYR corrected for 11CO2 and 
11C-labeled 
proteins) were used to calculate PSR in nanomoles per milliliter tumor tissue per minute 
(nmol/ml/min) using a modifi ed Patlak analysis 14. By visually masking nontumor regions 
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with physiologically high uptake of TYR (e.g. salivary glands), these regions were prevented 
from contributing to the average tumor time-activity curve. 
Semiquantitative analyses were also performed by calculation of standardized 
uptake values (SUV) and estimation of tumor-to-nontumor ratio (T/N) to compare absolute 
quantifi cation (PSR) with semiquantitative methods. The SUV based on bodyweight (SUVBW) 
was defi ned as the tumor tissue activity (MBq/ml) in a ROI, as measured by PET, divided by 
the injected dose (MBq) per kilogram bodyweight. In addition, nontumor uptake (N) was 
assessed from the right trapezius muscle and the T/N-ratio could be calculated. SUVBW and 
T/N-ratio were calculated from the summed data obtained of the last three frames (20-50 
min postinjection) to reconstruct one static scan.
Statistical analysis
To quantify the degree of correlation between PET results and histological parameters, 
a two-tailed Spearman test (non-parametric parameters) or Pearson test (parametric 
parameters) correlation analysis was performed. Comparison of the histological grading 
between the larynx specimen and the biopsy was assessed by a Spearman test. One-way 
analysis of variance (ANOVA) was used to assess diff erences between grading groups. A 
p-value of <0.05 was considered to be signifi cant.
RESULTS
In the qualitative evaluation of TYR-PET studies, all 25 primary malignancies were identifi ed 
correctly (Fig. 1). The tumor PSR ranged from 0.87 to 6.96 nmol/ml/min (median 2.32 
nmol/ml/min). The median SUVBW and T/N-ratio of tumor tissue were 4.62 (range 1.85-
7.34) and 4.85 (range 2.33-9.09), respectively. In one patient, only SUV and T/N-ratio could 
be calculated, due to the absence of arterial canulation for technical reasons. 
Figure 1. 
TYR-PET scan of a patient with a T2 N0 supraglottic laryngeal 
squamous cell carcinoma.
UICC grading showed 9 well diff erentiated (G1), 10 moderately diff erentiated (G2), 
and 6 poorly diff erentiated (G3) tumors (Table 1). Glottic laryngeal carcinomas contained 
mainly high diff erentiated tumors (56% G1), whereas 76% of the supraglottic tumors were 
moderately (G2) or poorly (G3) diff erentiated. The mean PSR values for G1, G2 and G3 
tumors were 1.91 nmol/ml/min (range 1.14-3.75), 2.60 nmol/ml/min (range 0.87-6.96) and 
3.49 nmol/ml/min (1.62-5.12), respectively (Fig. 2a). Statistical analysis (one-way ANOVA) 

























































Tumor grade (G1= well diff erentiated; G2= 
moderately diff erentiated and G3= poorly 
diff erentiated) versus  protein synthesis rate 
(PSR) (Figure 2a), standardized uptake values 
(SUVBW) (Figure 2b) and tumor-to-nontumor 
ratio (T/N) (Figure 2c) as measured by PET of 
laryngeal and hypopharyngeal carcinomas. 
Mean values are refl ected as horizontal lines 
in each grading group. A tendency  (p=0.083) 
was observed between PSR values and grade.
G3 tumors. Diff erences in SUV and T/N-ratio between the diff erent grading groups were 
not signifi cant either (Fig. 2b and 2c). When supraglottic tumors were evaluated separately, 
the mean PSR values for G1, G2 and G3 tumors were 1.55 nmol/ml/min (range 1.23-2.32), 
2.60 nmol/ml/min (range 2.40-2.81) and 4.69 nmol/ml/min (4.16-5.12), respectively (Fig. 
3). Although statistical analysis was not valid because of the limited number of patients, 
an association exists between increase of metabolic activity and loss of diff erentiation in 
tumors.
Mitotic activity ranged from 0.06-4.3% with a median value of 0.56%. No 
correlations were observed between the mitotic activity and PSR, SUVBW or T/N-ratio as 
measured by PET (Fig. 4). 












































Protein synthesis rate (PSR) as measured by 
TYR-PET versus tumor grade of supraglottic 
squamous cell carcimomas.
Figure 4. 
In vitro mitotic activity versus in vivo protein 
synthesis rate (PSR) as measured by TYR-PET. 
No signifi cant correlation (p=ns) could be 
found.
Darkly stained positive nuclei were clearly distinguished from negative nuclei (Fig. 5). Ki-67 
LI varied from 8% to 69% with a median percentage of 24%. No correlation was observed 
between the percentage of cells in proliferation and PSR, SUVBW or T/N-ratio (Fig. 6).  
Figure 5. 
Monoclonal antibody MIB-1 stained tissue sections of a supraglottic tumor (20x; fi gure 5a, 
and 200x; fi gure 5b, respectively) showing a low amount of proliferating cells. All dark nuclei 
express Ki-67 and have entered the cell cycle.
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The current study was set up to assess a relation between in vivo metabolic activity of 
laryngeal squamous cell carcinomas as measured by TYR-PET and in vitro biological 
parameters as determined by histopathological techniques. 
 The growth rate of tumors, and therefore metabolic activity, is an essential feature 
in their malignant potential. In histopathology, the malignancy grade is associated with 
the aggressiveness of growth. Although loss of diff erentiation in tumors results in a less 
effi  cient and therefore higher use of energy, and higher mitotic rate and proliferation 
activity require more energy, a clear correlation between histologic parameters and tumor 
metabolism has not been demonstrated. 
Ki-67 LI (%)





















Protein synthesis rate (PSR) as measured by TYR-PET versus proliferation activity. The correlation 
between PSR and the Ki-67 labeling index (LI) was not signifi cant.
PET versus histological grade
In FDG studies, a relation between histological grade and glucose uptake has been 
controversial. In patients with soft-tissue sarcomas 22, non-Hodgkin lymphomas 23 and 
brain tumors 24 FDG uptake was related to histological grading. However, a discrepancy 
between FDG uptake and grading was described in patients with head and neck cancer. 
In a FDG study on thirty-seven patients with diff erent head and neck tumors, Minn et al. 
described a strong association between high FDG uptake and low or moderate histological 
grade 9. However, in several other studies on head and neck tumors, no clear correlations 
were found 8,10,25. Correlations between histological grade and MET uptake were found in 
brain, lung and uterine cancer 26, but not in patients with head and neck carcinomas 27.
 TYR-PET studies for comparison with histological grading have been performed 
in brain and soft tissue sarcomas. Brain tumors demonstrated no correlations between 
histological grading and TYR uptake 15,28. In soft-tissue sarcomas, Kole et al. described 
a moderate correlation (r=0.58) between PSR and grade 29, while Plaat et al. could not 
confi rm this result 30. 
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In the present study with a small number of patients, the quantitative metabolic 
values did not diff er signifi cantly between the tumor grades, although a tendency (p=0.083) 
appears to be present. The diff erences were even more evident when supraglottic tumors 
were evaluated separately, suggesting a relationship between in vivo metabolic activity 
and tumor aggressiveness. Distiction between glottic and supraglottic tumors was made 
because of heterogeneity of laryngeal carcinomas. Although there is no overwelming 
evidence to support the view that tumors from diff erent sites of the larynx have intrinsic 
biological diff erences, supraglottic tumors do tend to be more moderately and poorly 
diff erentiated than glottic tumors 31. This is in accordance with the results of our study. 
PET versus proliferation and mitosis
High proliferative activity in tumors indicates that a high proportion of tumor cells has 
entered the cell division cycle (G1, S and G2 phases), whereas a high mitotic rate implies 
that a large number of cells is in the fi nal phase of the cell cycle (M phase). Proliferation 
and mitosis are markers of the biological behavior of malignant tumors 32. In patients with 
intracranial tumors and bronchial carcinomas, FDG uptake was shown to be related to 
proliferative activity 29. In head and neck tumors the results were not conclusive. Initial 
studies by Minn et al. 6 revealed a relation between glucose metabolism and proliferation 
of head and neck tumors based on DNA fl ow cytometry data. They suggested that the 
increase in glucose utilization in head and neck tumors is mainly needed for nucleic acid 
synthesis. However, in a FDG and fl ow cytometry study by Haberkorn et al., no linear 
correlation between FDG uptake and proliferation index was found 7. Only when the head 
and neck tumors were separated in groups with high and low FDG uptake, correlations 
could be demonstrated. These data suggest that other factors contribute to the uptake of 
FDG in tumors. Also in vitro studies using FDG-PET produced contradictive results. Higashi 
et al. found that FDG uptake did not correlate with proliferative activity, but strongly related 
to the number of viable tumor cells 8. A recent study using Ki-67 labeling demonstrated a 
correlation with FDG uptake and proliferation kinetics in head and neck tumors 33, which 
is in contrast to previously reported results 9.
 The outcome from studies comparing FDG and MET uptake with histopathological 
parameters are not conclusive either. Whereas Minn et al. 34 found that MET uptake 
represented proliferative activity and FDG was a marker of cell viability, the opposite 
conclusion was reached by Kubota et al. 35.
Studies comparing mitotic and proliferative activity with TYR uptake have been 
performed in brain and soft tissue sarcomas. In two studies of patients with various brain 
tumors, no correlation was found between proliferation and PSR, as measured with TYR-
PET 14,28. Two studies on soft tissue sarcomas demonstrated correlations between PSR 
and proliferation, but in only one study a relationship was observed with mitotic rate 
29,30. In the present study on patients with laryngeal carcinomas, no correlations were 
observed between mitotic rate or proliferative activity as measured by Ki-67 labeling and 
quantitative TYR-PET values. 
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Several diff erent explanations should be considered for the inconsistency in 
observations of the diff erent TYR-PET studies. Due to a restricted research setting of PET 
studies and the relatively low incidence of head and neck tumors, the number of patients 
is necessarily limited and heterogeneous. Furthermore, neoplasms diff er in heterogeneity 
on the cellular level, and may also be macroscopically heterogeneous, due to diff erences 
in distribution of cell populations, vascular structures, stroma and necrotic tissue. Schmidt 
et al. have demonstrated that tissue heterogeneity can have signifi cant eff ects on the 
quantitative parameter values 36. The diff erences in TYR-PET observations between brain 
tumors, soft tissue sarcomas and head and neck carcinomas may be caused by inter- and 
intratumor heterogeneity.
Also, in analyzing the relationship between tracer uptake and histological 
parameters, the intratumor heterogeneity of squamous cell carcinomas of the larynx 
may cause sampling errors in the histological evaluation. The TYR uptake, based on a 
standardized ROI analysis, encompasses the entire tumor, whereas histological parameters 
are evaluated on a representative tissue sample. Sampling errors were reduced by 
analyzing randomly selected microscopic areas within the tumor sample. Although we 
found relatively high correlations (r=0.87) between grading of the samples of the larynx 
specimen and the biopsies in the present study, sampling errors may still have occurred 
and have infl uenced the relations between histological parameters and PET results.
Cell proliferation has been demonstrated to increase in almost all tumors and 
is often measured by immunostaining the Ki-67 protein. However, several reports 
demonstrated that Ki-67 does not have prognostic value in predicting therapy outcome 
of head and neck tumors 31. The limited number of patients and the heterogeneity of the 
tumors was often mentioned as explanation for these results, but it can also be argued 
that Ki-67 is not the optimal parameter for assessment of tumor growth of head and neck 
tumors. Furthermore, proliferative activity does not seem to have a signifi cant relationship 
to histopathological grading in head and neck tumors 37. This could explain the fact that 
in the present study a relation was observed between TYR uptake and grade, but not 
between TYR uptake and proliferative activity. In vivo metabolic activity of tumors has 
been suggested to be related to the behavior of the disease, and in head and neck tumors, 
FDG uptake was demonstrated to be a prognostic factor 9. Our results suggest that in 
vivo metabolic activity using TYR-PET refl ects tumor aggressiveness since an association 
was observed between TYR uptake and tumor grade, but not with proliferation or mitotic 
activity of laryngeal squamous cell carcinomas. Further investigation of histopathological 
and biological parameters in larger series of patients with laryngeal carcinomas is essential 
for assessment of future applications of TYR-PET. On the other hand, the development 
of future histopathological tumormarkers may reveal other relationships between 
histopathology and PET.
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CONCLUSIONS
In the present study the relationships between in vivo tumor metabolism using TYR-
PET and in vitro biological activity as refl ected by tumor grade, mitotic and proliferative 
activity of laryngeal squamous cell carcinomas, were investigated. An association was 
found between TYR uptake and tumor grade, but not with the number of mitoses or 
the amount of proliferating cells measured by Ki-67 immunostaining. These results may 
suggest a relation between in vivo TYR uptake and aggressiveness of tumor growth.
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